

Driving T1D Cures During Challenging Times

Through our commitment and focus, JDRF has played a role in nearly every major type 1 diabetes (T1D) advance—every drug, device, cell therapy. People with T1D are doing better today, thanks to significant investments by JDRF to improve the lives of millions affected by the disease. And even during the challenges of the coronavirus pandemic, we remained laser-focused on curing this disease.

FY21 Mission Progress

Curing T1D is JDRF’s ultimate goal. Until we have cures, we help people with T1D live healthier lives. And in the past year, we have seen incredible progress.



Four FDA-approved artificial pancreas systems, other improved technologies, and advanced insulins, are helping to reduce dangerous highs and lows and the burden of life with T1D.



Cell Therapies are in human clinical trials and so far, are yielding outstanding results.



Teplizumab, a drug shown to delay onset of T1D for up to 3 years, is under FDA review.




We have a diversified, **global research strategy** involving different kinds of cures and improving-lives therapies—all with multiple projects underway.

Leverage Leads the Way

A global leader in the pursuit of insulin independence for people living with diabetes, JDRF accelerates the path to cures by raising funds and allocating them to T1D research and therapy development, as well as by leveraging our expertise and leadership to bring in additional funding and supporters. This leverage is a key part of JDRF’s strategy to accelerate cures and life-improving therapies. It has empowered us to grow global support of and investment in T1D research, year-over-year.

Fiscal Year 2021 (FY21), the first, full fiscal year of the coronavirus pandemic, we saw:



JDRF invested \$57.3M in research in FY21, and through our influence within the public and private sectors, we helped raise another \$425.7M

A total of \$483 million—through funding from other organizations, corporations, and governments, in addition to JDRF—for T1D research and therapy development


Of that \$483 million, **JDRF T1D Fund**—our venture philanthropy fund established to address the lack of private investment in T1D therapy research and development—catalyzed **\$213M*** in private investment in companies developing T1D treatments

*This \$213M accounts for the majority of the \$228.2M of the "Industry Partnerships and Investments" section in the triangle graphic left

More than Three-Quarters of a Billion Dollars to Cures and Improving Lives

During the past 4 fiscal years, through JDRF's research grants and JDRF T1D Fund investments (those that we have made, as well as private, alongside investments), **\$779.3M** has been directed to cure T1D and improve lives—with most of it (approximately 83%) focused on cures.

JDRF Grants and T1D Fund Investments: FY18 through FY21




FY21 JDRF Financials

For the entirety of FY21, the pandemic upended JDRF's events-based fundraising model. Still, through our expertise and influence, we led our partners in the private and public sectors to help grow year-over-year total, global support of T1D therapy development and access.

Significant Pandemic Impact

JDRF's experience is similar to the experiences of other voluntary health and welfare organizations. Because of the pandemic, our Peer 2 Peer and signature fundraising events brought in about 25 percent less revenue compared to what they brought in for FY20.

In FY21, since we raised fewer funds that could be directed to research grants, research support, advocacy, and public education/community engagement, we were forced to reduce our mission spend in those areas.



Factors driving T1D Fund contributions and investment gains include:

Given the interest from our leadership giving donors, the T1D Fund held a successful capital campaign and raised over **\$50 million during the last two years, \$30 million of which was raised in FY21.**

Merck acquired T1D Fund portfolio company, Pandion Therapeutics for about **\$1.85B (billion).**

The T1D Fund's first—and successful—international efforts in Canada and the United Kingdom.

Revenue Growth, T1D Fund Success, and Positive Outlook

JDRF has four main revenue streams: Events; Contributions; Investment Gains/Losses; and International Affiliates/other.

Even though our events revenue decreased, because of the generosity and dedication of our leadership giving donors, we saw growth in total revenue for FY21 (15% increase from total revenue for FY20).

This revenue growth was largely driven by success of the JDRF T1D Fund's large capital campaign. The Fund has transformed the fight to cure T1D by successfully activating the T1D life sciences market.


In FY21, three of JDRF's four revenue streams—Contributions, Investment Gains/Losses, and International Affiliates/Other—saw increases that were in part due to JDRF T1D Fund donations or investment gains, which legally, must be used for the Fund.

All donations to the T1D Fund are included in JDRF's revenue, as are gains and losses on the Fund's investments.

Because the Fund is no longer actively fundraising, this year's revenue growth driven by the Fund is not expected to continue into the future.

We had a strong finish to FY21 and we have a bright outlook for the future.

For FY22 we are significantly increasing our mission spend (compared to FY21), including funding for research grants and research support.



**Of the \$93M contributions raised, \$30M was restricted to the T1D Fund, \$21M of which was in the form of multi-year pledges as of June 30, 2021. Of the \$47.4M in investment gains, \$27M was related to the T1D Fund. All Fund contributions and investment gains are generally deployed in future years as part of our strategic capital deployment schedule as governed by the Fund's investment committee.*

JDRF T1DFund

FY21 revenue growth driven by the Fund shows that the Fund is doing exactly what we established it to do: address the challenge of low private venture capital investment in the T1D life sciences market.

As a result of the T1D Fund's efforts, the number of companies with T1D cure programs in development has risen from just a handful in 2016 (when we established the Fund) to approximately 30 today, and nearly \$600 million of new private capital has been invested alongside the Fund since inception.

These companies are achieving early mission success via new clinical trials, industry partnerships with pharma, and application of the knowledge base for curing and treating other diseases with biology relevant to T1D.

Donations to the Fund and returns on the Fund's investments are exclusively for investment in early-stage life science companies with goals aligned to JDRF's mission.

Funds raised for the T1D Fund cannot be spent on our research grants, research support, public education, advocacy, fundraising, and management/general. This helps explain why total revenue increased in FY21 while core research and mission expenses decreased.



2022

Every gift takes us one step closer to curing T1D. Find out how you can support JDRF and make a difference in the lives of people with T1D by visiting jdrf.org/donate.

You can also follow us on:

 facebook.com/myjdrf

 [@JDRF/@JDRFResearch](https://twitter.com/JDRF)

 [@JDRFHQ](https://instagram.com/JDRFHQ)

 youtube.com/user/jdrfonline